APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension (PAH) Medicine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook and Growth Opportunities 2026

29 December 2025199 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension (PAH) Medicine Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension (PAH) Medicine Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension (PAH) Medicine Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension (PAH) Medicine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension (PAH) Medicine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Arterial Hypertension (PAH) Medicine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Arterial Hypertension (PAH) Medicine market include Actelion Pharmaceuticals, Gilead Sciences, United Therapeutics Corporation, Pfizer and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pulmonary Arterial Hypertension (PAH) Medicine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Arterial Hypertension (PAH) Medicine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Arterial Hypertension (PAH) Medicine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pulmonary Arterial Hypertension (PAH) Medicine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Company

Actelion Pharmaceuticals

Gilead Sciences

United Therapeutics Corporation

Pfizer

Eli Lilly

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Type

Calcium Channel Blockers

Novel Targeted Drugs

Other

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Application

Secondary Pulmonary Hypertension (SPH)

Primary Pulmonary Hypertension (PPH)

Pulmonary Arterial Hypertension (PAH) Medicine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pulmonary Arterial Hypertension (PAH) Medicine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pulmonary Arterial Hypertension (PAH) Medicine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Arterial Hypertension (PAH) Medicine significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Arterial Hypertension (PAH) Medicine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension (PAH) Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension (PAH) Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension (PAH) Medicine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Arterial Hypertension (PAH) Medicine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Arterial Hypertension (PAH) Medicine industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension (PAH) Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pulmonary Arterial Hypertension (PAH) Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pulmonary Arterial Hypertension (PAH) Medicine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends Table 2. Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers Table 3. Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges Table 4. Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints Table 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Company (2021-2026) Table 9. Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pulmonary Arterial Hypertension (PAH) Medicine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pulmonary Arterial Hypertension (PAH) Medicine Key Company Manufacturing Base & Headquarters Table 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Company, Product Type & Application Table 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pulmonary Arterial Hypertension (PAH) Medicine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Calcium Channel Blockers Table 18. Significant Companies of Novel Targeted Drugs Table 19. Significant Companies of Other Table 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Type (2021-2026) Table 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Type (2027-2032) Table 25. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type (2021-2026) Table 29. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Secondary Pulmonary Hypertension (SPH) Table 31. Significant Companies of Primary Pulmonary Hypertension (PPH) Table 32. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Application (2021-2026) Table 36. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Application (2027-2032) Table 37. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application (2021-2026) Table 41. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application (2027-2032) Table 42. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2026) & (K Units) Table 44. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2021-2026) Table 45. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2027-2032) & (K Units) Table 46. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region (2027-2032) Table 47. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Region (2021-2026) Table 50. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Region (2027-2032) Table 52. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Pulmonary Arterial Hypertension (PAH) Medicine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026) & (K Units) Table 57. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2021-2026) Table 58. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032) & (K Units) Table 59. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Country (2027-2032) Table 60. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Market Share by Country (2021-2026) Table 62. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Market Share by Country (2027-2032) Table 64. Actelion Pharmaceuticals Company Information Table 65. Actelion Pharmaceuticals Business Overview Table 66. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 68. Actelion Pharmaceuticals Recent Development Table 69. Gilead Sciences Company Information Table 70. Gilead Sciences Business Overview Table 71. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 73. Gilead Sciences Recent Development Table 74. United Therapeutics Corporation Company Information Table 75. United Therapeutics Corporation Business Overview Table 76. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 78. United Therapeutics Corporation Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 83. Pfizer Recent Development Table 84. Eli Lilly Company Information Table 85. Eli Lilly Business Overview Table 86. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio Table 88. Eli Lilly Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Pulmonary Arterial Hypertension (PAH) Medicine Distributors List Table 92. Pulmonary Arterial Hypertension (PAH) Medicine Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Medicine Product Image Figure 2. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (2021-2032) & (K Units) Figure 5. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pulmonary Arterial Hypertension (PAH) Medicine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Calcium Channel Blockers Image Figure 10. Novel Targeted Drugs Image Figure 11. Other Image Figure 12. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Type (2021-2032) Figure 15. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type (2021-2032) Figure 18. Secondary Pulmonary Hypertension (SPH) Image Figure 19. Primary Pulmonary Hypertension (PPH) Image Figure 20. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Application (2021-2032) Figure 23. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application (2021-2032) Figure 26. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Pulmonary Arterial Hypertension (PAH) Medicine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Calcium Channel Blockers
  • Novel Targeted Drugs
  • Other
Applications
  • Secondary Pulmonary Hypertension (SPH)
  • Primary Pulmonary Hypertension (PPH)
Companies covered
  • Actelion Pharmaceuticals
  • Gilead Sciences
  • United Therapeutics Corporation
  • Pfizer
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  4. 1.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume (2021-2032)
  5. 1.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension (PAH) Medicine Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension (PAH) Medicine Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension (PAH) Medicine Industry Restraints
3 Pulmonary Arterial Hypertension (PAH) Medicine Market by Company
  1. 3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Company (2021-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Average Price by Company (2021-2026)
  5. 3.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Ranking (2024-2026)
  6. 3.6 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Manufacturing Base and Headquarters
  7. 3.7 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Product Type and Application
  8. 3.8 Global Pulmonary Arterial Hypertension (PAH) Medicine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pulmonary Arterial Hypertension (PAH) Medicine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pulmonary Arterial Hypertension (PAH) Medicine Market by Type
  1. 4.1 Pulmonary Arterial Hypertension (PAH) Medicine Type Introduction
  2. 4.1.1 Calcium Channel Blockers
  3. 4.1.2 Novel Targeted Drugs
  4. 4.1.3 Other
  5. 4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type
  6. 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type
  10. 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type (2021-2032)
5 Pulmonary Arterial Hypertension (PAH) Medicine Market by Application
  1. 5.1 Pulmonary Arterial Hypertension (PAH) Medicine Application Introduction
  2. 5.1.1 Secondary Pulmonary Hypertension (SPH)
  3. 5.1.2 Primary Pulmonary Hypertension (PPH)
  4. 5.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application
  5. 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application
  9. 5.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application (2021-2032)
6 Pulmonary Arterial Hypertension (PAH) Medicine Regional Sales and Value Analysis
  1. 6.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Region (2027-2032)
  5. 6.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Region (2027-2032)
  9. 6.5 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  12. 6.6.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  15. 6.7.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  21. 6.9.2 South America Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Arterial Hypertension (PAH) Medicine Country-level Sales and Value Analysis
  1. 7.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2032)
  4. 7.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2021-2026)
  5. 7.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales by Country (2027-2032)
  6. 7.4 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pulmonary Arterial Hypertension (PAH) Medicine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Actelion Pharmaceuticals
  2. 8.1.1 Actelion Pharmaceuticals Company Information
  3. 8.1.2 Actelion Pharmaceuticals Business Overview
  4. 8.1.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  6. 8.1.5 Actelion Pharmaceuticals Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 United Therapeutics Corporation
  14. 8.3.1 United Therapeutics Corporation Company Information
  15. 8.3.2 United Therapeutics Corporation Business Overview
  16. 8.3.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  18. 8.3.5 United Therapeutics Corporation Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pulmonary Arterial Hypertension (PAH) Medicine Value Chain Analysis
  2. 9.1.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pulmonary Arterial Hypertension (PAH) Medicine Sales Mode & Process
  6. 9.2 Pulmonary Arterial Hypertension (PAH) Medicine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
  9. 9.2.3 Pulmonary Arterial Hypertension (PAH) Medicine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst